Nicole Palomba

Dr. Nicole Palomba

IRCCS Neuromed
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VNViviana Nociti
Viviana Nociti
MSMassimo Santoro
Massimo Santoro
DQDavide Quaranta
Davide Quaranta
FLFrancesco Antonio Losavio
Francesco Antonio Losavio
CFChiara De Fino
Chiara De Fino
MMMassimiliano Mirabella
Massimiliano Mirabella
Brain-Derived Neurotrophic Factor (BDNF) and its most common polymorphism Val66Met are known to have a role in Multiple Sclerosis (MS) pathogenesis. Evidence is accumulating that there is an involvement of DNA methylation in the regulation of BDNF expression. The aim of this study was to assess in blood samples of MS patients the correlation between the methylation status of the CpG site near BDNF-Val66Met polymorphism and the severity of the disease. We recruited 209 MS patients that were genotyped for the BDNF Val66Met polymorphism. For each patient we quantitatively measured the methylation level of cytosine included in the exonic CpG site that can be created or abolished by the Val66Met BDNF polymorphism. Furthermore, we analyzed the clinical history of each patient and determined the time elapsed since the onset of the disease and an EDSS score of 6.0. The genetic analysis identified 122 (58.4%) subjects carrying the Val/Val genotype, 81 (38.8%) with Val/Met genotype, and 6 (2.8%) carrying the Met/Met genotype. When the endpoint of an EDSS score of 6 was taken into account by means of a survival analysis, 52 failures (i.e., reaching an EDSS score of 6) were reported. When the sample was stratified according to the percentage of the BDNF methylation, subjects falling below the median (median methylation = 81%) were at higher risk of failure (IRD = 0.016; 95%CI = 0.0050–0.0279; p = 0.004). In patients with a high disease progression the hypomethylation of the BDNF gene could increase the secretion of the protective neurotrophin, so epigenetic modifications could be the organism response to limit a brain functional reserve loss. Our study suggests that the percentage of methylation of the BDNF gene could be used as a prognostic factor for disease progression toward a high disability in MS patient.

15 February 2021 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
NPNicole Palomba
Nicole Palomba
KMkatiuscia Martinello
katiuscia Martinello
GCGermana Cocozza
Germana Cocozza
SCSara Casciato
Sara Casciato
AMAddolorata Mascia
Addolorata Mascia
SFSergio Fucile
Sergio Fucile
Background: Intracellular Ca2+modulates several microglial activities, such as proliferation, migration, phagocytosis, and inflammatory mediator secretion. Extracellular ATP, the levels of which significantly change during epileptic seizures, activates specific receptors leading to an increase of intracellular free Ca2+concentration ([Ca2+]i). Here, we aimed to functionally characterize human microglia obtained from cortices of subjects with temporal lobe epilepsy, focusing on the Ca2+-mediated response triggered by purinergic signaling.Methods: Fura-2 based fluorescence microscopy was used to measure [Ca2+]iin primary cultures of human microglial cells obtained from surgical specimens. The perforated patch-clamp technique, which preserves the cytoplasmic milieu, was used to measure ATP-evoked Ca2+-dependent whole-cell currents.Results: In human microglia extracellular ATP evoked [Ca2+]iincreases depend on Ca2+entry from the extracellular space and on Ca2+mobilization from intracellular compartments. Extracellular ATP also induced a transient fivefold potentiation of the total transmembrane current, which was completely abolished when [Ca2+]iincreases were prevented by removing external Ca2+and using an intracellular Ca2+chelator. TRAM-34, a selective KCa3.1 blocker, significantly reduced the ATP-induced current potentiation but did not abolish it. The removal of external Cl−in the presence of TRAM-34 further lowered the ATP-evoked effect. A direct comparison between the ATP-evoked mean current potentiation and mean Ca2+transient amplitude revealed a linear correlation. Treatment of microglial cells with LPS for 48 h did not prevent the ATP-induced Ca2+mobilization but completely abolished the ATP-mediated current potentiation. The absence of the Ca2+-evoked K+current led to a less sustained ATP-evoked Ca2+entry, as shown by the faster Ca2+transient kinetics observed in LPS-treated microglia.Conclusions: Our study confirms a functional role for KCa3.1 channels in human microglia, linking ATP-evoked Ca2+transients to changes in membrane conductance, with an inflammation-dependent mechanism, and suggests that during brain inflammation the KCa3.1-mediated microglial response to purinergic signaling may be reduced.

12 January 2016 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Massimo SantoroMassimo Santoro
Massimo Santoro
VNV. Nociti
V. Nociti
CFC. De Fino
C. De Fino
ACA. Caprara
A. Caprara
RGR. Giordano
R. Giordano
DQD. Quaranta
D. Quaranta

12 May 2022 in Life
Verified
Journal Article
Open access
PDF file
RSRosita Stanzione
Rosita Stanzione
MCMaria Cotugno
Maria Cotugno
Maurizio ForteMaurizio Forte
Maurizio Forte
FBFranca Bianchi
Franca Bianchi
SMSimona Marchitti
Simona Marchitti
SRSperanza Rubattu
Speranza Rubattu
The mitochondrial uncoupling protein 2 (UCP2) acts as an anion transporter and as an antioxidant factor able to reduce the reactive oxygen species level. Based on its effects, UCP2 prevents the membrane lipids, proteins, and DNA damage while preserving normal cellular functions. Many variants have been identified within the human UCP2. Some of them were associated with a higher risk of obesity, diabetes and cardiovascular diseases in different populations. UCP2 appears a suitable candidate also for the risk of ischemic stroke. In the current study, we investigated the possible association between few variants of UCP2 (rs659366, rs660339, rs1554995310) and the risk of ischemic stroke in a genetically homogenous cohort of cases and controls selected in Sardinia Island. This population has been previously analysed for other candidate genes. A total of 250 cases of ischemic stroke and 241 controls were enrolled in the study. The allelic/genotypic distribution of the 3 UCP2 variants was characterized and compared among cases and controls. The results of our study confirmed known risk factors for ischemic stroke: age, history of smoking, hypertension, hypercholesterolemia, and atrial fibrillation. No association was found between the 3 UCP2 variants and the risk of ischemic stroke in our Sardinian cohort.

21 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VNViviana Nociti
Viviana Nociti
MSMassimo Santoro
Massimo Santoro
DQDavide Quaranta
Davide Quaranta
FLFrancesco Antonio Losavio
Francesco Antonio Losavio
CFChiara De Fino
Chiara De Fino
MMMassimiliano Mirabella
Massimiliano Mirabella
[This corrects the article DOI: 10.1371/journal.pone.0206140.].

Verified
Journal Article
Open access
PDF file
FNFilomena Napolitano
Filomena Napolitano
GBGiorgia Bruno
Giorgia Bruno
CTChiara Terracciano
Chiara Terracciano
GFGiuseppina Franzese
Giuseppina Franzese
NPNicole Palomba
Nicole Palomba
TETeresa Esposito
Teresa Esposito
Pompe disease is an autosomal recessive disorder caused by a deficiency in the enzyme acid alpha-glucosidase. The late-onset form of Pompe disease (LOPD) is characterized by a slowly progressing proximal muscle weakness, often involving respiratory muscles. In LOPD, the levels of GAA enzyme activity and the severity of the clinical pictures may be highly variable among individuals, even in those who harbour the same combination of GAA mutations. The result is an unpredictable genotype–phenotype correlation. The purpose of this study was to identify the genetic factors responsible for the progression, severity and drug response in LOPD. We report here on a detailed clinical, morphological and genetic study, including a whole exome sequencing (WES) analysis of 11 adult LOPD siblings belonging to two Italian families carrying compound heterozygous GAA mutations. We disclosed a heterogeneous pattern of myopathic impairment, associated, among others, with cardiac defects, intracranial vessels abnormality, osteoporosis, vitamin D deficiency, obesity and adverse response to enzyme replacement therapy (ERT). We identified deleterious variants in the genes involved in autophagy, immunity and bone metabolism, which contributed to the severity of the clinical symptoms observed in the LOPD patients. This study emphasizes the multisystem nature of LOPD and highlights the polygenic nature of the complex phenotype disclosed in these patients.